GLP-1 T

GLP-1 T (GLP-1 / GIP) Overview

Tirzepatide (Research Grade) is a next-generation, lipidated GIP/GLP-1 dual agonist peptide used in metabolic research to explore glucose control, appetite signaling, body-weight pathways, sleep-disordered breathing in obesity, and liver-metabolic health (MASH/NASH). Tirzepatide is primarily dual, though it has some glucagon receptor activity at higher doses. Research is ongoing and the claimed benefits are still emerging.

GLP-1 / GIP Structure:

CAS Number: 2023788-19-2

Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight: ≈ 4813.5 g/mol

Parent Compound: Unimolecular dual GIP/GLP-1 agonist

Monoisotopic Mass: ≈ 4810.52 Da

Synonyms:

• LY3298176
• Tirzepatida
• Mounjaro®
• Zepbound® (brand names noted for scientific context only)

Research Areas:

• Type 2 diabetes: insulin secretion/sensitivity, glycemic regulation models.
• Obesity & weight-management biology: appetite signaling, gastric emptying, energy intake.
• Obstructive sleep apnea (OSA) in obesity: mechanisms linking weight loss and airway events (FDA approved for OSA under brand Zepbound; listed here for context).
• Liver/metabolic disease (MASH/NASH, NAFLD): inflammation, steatosis, and fibrosis endpoints.
• Cardiometabolic outcomes: ongoing/reported work vs GLP-1

Research-only note: GLP-1 T is not FDA-approved for therapeutic use; published effects are primarily preclinical and exploratory.